{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Low-grade+NMIBC",
    "query": {
      "condition": "Low-grade NMIBC"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T20:57:51.529Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06995677",
      "title": "Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Low-grade NMIBC",
        "FGFR Gene Amplification",
        "FGFR Gene Alterations",
        "FGFR3 Gene Alteration",
        "FGFR3 Gene Mutation",
        "FGFR3 Gene Fusions"
      ],
      "interventions": [
        {
          "name": "TYRA-300 60mg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 50mg",
          "type": "DRUG"
        },
        {
          "name": "TYRA-300 Dose TBD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2025-06-27",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-06-25T20:57:51.529Z",
      "location_count": 30,
      "location_summary": "Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 27 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago Ridge",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06995677"
    },
    {
      "nct_id": "NCT03081858",
      "title": "Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer Cell Transitional",
        "Non-Muscle Invasive Bladder Cancer",
        "Bladder Cancer",
        "Urinary Bladder",
        "Transitional Cell Carcinoma of the Bladder",
        "Urinary Bladder Neoplasms",
        "Urologic Neoplasms",
        "Urogenital Neoplasms",
        "Urinary Bladder Diseases",
        "Urologic Diseases"
      ],
      "interventions": [
        {
          "name": "TSD-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lipac Oncology LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 15,
      "start_date": "2018-05-17",
      "completion_date": "2021-08-05",
      "has_results": true,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-06-25T20:57:51.529Z",
      "location_count": 5,
      "location_summary": "Tucson, Arizona • Bakersfield, California • Los Angeles, California + 2 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hanover",
          "state": "Maryland"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03081858"
    },
    {
      "nct_id": "NCT06637423",
      "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab tirumotecan",
          "type": "DRUG"
        },
        {
          "name": "Rescue medication",
          "type": "DRUG"
        },
        {
          "name": "Supportive care measures",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2024-12-20",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-06-25T20:57:51.529Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • Tampa, Florida • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06637423"
    },
    {
      "nct_id": "NCT03558503",
      "title": "A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "UGN-102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2018-10-15",
      "completion_date": "2020-10-21",
      "has_results": true,
      "last_update_posted_date": "2022-09-16",
      "last_synced_at": "2026-06-25T20:57:51.529Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Pompano Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03558503"
    },
    {
      "nct_id": "NCT04688931",
      "title": "A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "UGN-102",
          "type": "DRUG"
        },
        {
          "name": "TURBT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 282,
      "start_date": "2021-02-19",
      "completion_date": "2023-03-17",
      "has_results": true,
      "last_update_posted_date": "2024-06-06",
      "last_synced_at": "2026-06-25T20:57:51.529Z",
      "location_count": 33,
      "location_summary": "Tucson, Arizona • Loma Linda, California • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04688931"
    },
    {
      "nct_id": "NCT06331299",
      "title": "A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "UGN-103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2024-08-29",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-06-25T20:57:51.529Z",
      "location_count": 17,
      "location_summary": "Loma Linda, California • San Diego, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Powder Springs",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06331299"
    },
    {
      "nct_id": "NCT05243550",
      "title": "A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "UGN-102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 240,
      "start_date": "2022-03-01",
      "completion_date": "2028-03",
      "has_results": true,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-06-25T20:57:51.529Z",
      "location_count": 16,
      "location_summary": "Tucson, Arizona • Loma Linda, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05243550"
    },
    {
      "nct_id": "NCT05136898",
      "title": "Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [
        {
          "name": "UGN-102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UroGen Pharma Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2021-11-30",
      "completion_date": "2023-02-02",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-06-25T20:57:51.529Z",
      "location_count": 5,
      "location_summary": "Homewood, Alabama • Indianapolis, Indiana • Greensboro, North Carolina + 2 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Greensboro",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05136898"
    }
  ]
}